CO6400182A2 - Suspensión farmacéutica de liberación doble - Google Patents

Suspensión farmacéutica de liberación doble

Info

Publication number
CO6400182A2
CO6400182A2 CO11096477A CO11096477A CO6400182A2 CO 6400182 A2 CO6400182 A2 CO 6400182A2 CO 11096477 A CO11096477 A CO 11096477A CO 11096477 A CO11096477 A CO 11096477A CO 6400182 A2 CO6400182 A2 CO 6400182A2
Authority
CO
Colombia
Prior art keywords
active
pharmaceutically acceptable
release pharmaceutical
optionally
solution
Prior art date
Application number
CO11096477A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Sanju Dhawan
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CO6400182A2 publication Critical patent/CO6400182A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen suspensiones farmacéuticas de liberación doble que se suministran oralmente, que tienen una primera porción que comprende una forma de liberación inmediata del activo en la forma de solución o gránulos o forma suspendida en el vehículo/medio preferiblemente en la forma de solución y una segunda porción que comprende una forma de liberación sostenida del activo en la forma de microgránulos/micropartículas suspendidos en la fracción de liberación inmediata del agente activo solubilizado que comprende un núcleo y al menos una cubierta apropiada para forma de dosificación líquida para la administración de los ingredientes activos, en donde el núcleo comprende al menos un agente activo o sus sales, derivados, isómeros, polimorfos, solvatos, hidratos, análogos, enantiómeros, formas tautoméricas farmacéuticamente aceptables o mezclas de los mismos; opcionalmente al menos uno no soluble en agua, y opcionalmente uno o más excipientes farmacéuticamente aceptables; y al menos una cubierta que comprende al menos un polímero no soluble en agua independiente del pH junto con uno o más excipientes farmacéuticamente aceptables.
CO11096477A 2009-01-09 2011-08-01 Suspensión farmacéutica de liberación doble CO6400182A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN30DE2009 2009-01-09

Publications (1)

Publication Number Publication Date
CO6400182A2 true CO6400182A2 (es) 2012-03-15

Family

ID=42541723

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11096477A CO6400182A2 (es) 2009-01-09 2011-08-01 Suspensión farmacéutica de liberación doble

Country Status (10)

Country Link
US (1) US20110268808A1 (es)
EP (1) EP2385823A4 (es)
JP (1) JP2012514632A (es)
AU (1) AU2010211980A1 (es)
CO (1) CO6400182A2 (es)
MX (1) MX2011007399A (es)
PE (1) PE20110837A1 (es)
RU (1) RU2011133020A (es)
SG (1) SG172833A1 (es)
WO (1) WO2010089767A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351584B (es) 2011-03-04 2017-10-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EP2790729A4 (en) * 2011-12-12 2015-08-12 Orbis Biosciences Inc PARTICULATE FORMULATIONS WITH DELAYED RELEASE
US8927529B2 (en) 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
US9763928B2 (en) * 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
RU2016147008A (ru) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Жидкие композиции метформина с пролонгированным высвобождением
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
AU2015254875A1 (en) * 2014-05-01 2016-11-17 Sun Pharmaceutical Industries Limited Extended release suspension compositions
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
LT3273953T (lt) 2015-03-27 2019-02-25 Grünenthal GmbH Stabili kompozicija, skirta tapentadolio skyrimui parenteriniu būdu
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
EP3515412A1 (en) 2016-09-23 2019-07-31 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
WO2019199505A1 (en) * 2018-04-10 2019-10-17 Panacea Biomatx, Inc. Method and system for making personalized nutritional and pharmaceutical formulations using additive manufacturing
CN108926530A (zh) * 2018-08-17 2018-12-04 江苏科瑞达药业有限公司 一种具有高效混悬作用的对乙酰氨基酚液体制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503014A (ja) * 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド 剤形及び関連する治療法
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
FR2872044B1 (fr) * 2004-06-28 2007-06-29 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
KR20090015103A (ko) * 2006-06-01 2009-02-11 쉐링 코포레이션 페닐에프린 펄스 방출 제형 및 약제학적 조성물
DE602007006950D1 (de) * 2006-06-02 2010-07-15 Glaxosmithkline Llc Benzimidazol-substituierte thiophenderivate mit wirkung auf plk
WO2008122993A1 (en) * 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles

Also Published As

Publication number Publication date
SG172833A1 (en) 2011-08-29
WO2010089767A1 (en) 2010-08-12
MX2011007399A (es) 2011-11-18
EP2385823A1 (en) 2011-11-16
JP2012514632A (ja) 2012-06-28
US20110268808A1 (en) 2011-11-03
PE20110837A1 (es) 2011-11-27
RU2011133020A (ru) 2013-02-20
EP2385823A4 (en) 2014-02-12
AU2010211980A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
CO6400182A2 (es) Suspensión farmacéutica de liberación doble
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
SMT201500317B (it) Forma di dosaggio farmaceutica per la somministrazione orale di un inibitore della famiglia di bcl-2
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
AR060234A1 (es) Gel de suspension espumable
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
AR072245A1 (es) Proceso para minimizar el polimorfismo, forma de dosaje de dispersion rapida solida oral
NI201100154A (es) Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
DOP2015000028A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
PE20241347A1 (es) MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
MX2015005837A (es) Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo.
CO2019002616A2 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
UY37550A (es) Nueva formulación que comprende un derivado de bencimidazol
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
GT200600353A (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph.
AR044004A1 (es) Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones
AR082022A1 (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Legal Events

Date Code Title Description
FA Application withdrawn